News

CLINUVEL
Posted by CLINUVEL
November 24, 2021

CLINUVEL Kommuniqué V

CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.

Read More
Lachlan Hay
Posted by Lachlan Hay
November 22, 2021

CLINUVEL Communiqué V

CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...

Read More
CLINUVEL
Posted by CLINUVEL
November 18, 2021

CLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

Results of Annual General Meeting 2021

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

Chair Address

CLINUVEL PHARMACEUTICALS LTD today released its third Strategic Update.

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

CEO's Address - 2021 Annual General Meeting

2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen

Read More
Lachlan Hay
Posted by Lachlan Hay
November 8, 2021

CLINUVEL Expands Pharmaceutical Portfolio

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Read More
Lachlan Hay
Posted by Lachlan Hay
November 8, 2021

Strategic Update III

CLINUVEL PHARMACEUTICALS LTD today released its third Strategic Update.

Read More
CLINUVEL
Posted by CLINUVEL
November 8, 2021
CLINUVEL
Posted by CLINUVEL
November 8, 2021

CLINUVEL Adds ACTH to Portfolio

Melbourne, Australia, 08 November 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
We use cookies to give you the best experience.